Products

Westren Pharma Atorvastatin Calcium Tablets for Human Medicine Tablet
Westren Pharma Atorvastatin Calcium Tablets for Human Medicine Tablet

Westren Pharma Atorvastatin Calcium Tablets for Human Medicine Tablet

China Westren Pharma Atorvastatin Calcium Tablets for Human Medicine Tablet, Find details about China Atorvastatin Calcium, Atorvastatin from Westren Pharma Atorvastatin Calcium Tablets for Human Medicine Tablet

Model NO.
tablets
Pharmaceutical Technology
Chemical Synthesis
Dosage
10mg
Use
Orel
Transport Package
Box
Specification
10mg
Origin
China
Model NO.
tablets
Pharmaceutical Technology
Chemical Synthesis
Dosage
10mg
Use
Orel
Transport Package
Box
Specification
10mg
Origin
China
About
KEEP OUT OF REACH OF CHILDREN
WE CAN PROVIDE MAKE FORMEULATION (OEM)
 
 
 
Service we can provide:
1. Mixed container, we can mix different items in one container.
2. Quality control, before shipment, free sample for test. After shipment, keep sample for 3 years
3. Prompt shipment with professional documents
4. Packing as your request, with photo before shipment.
 
 
Product NameAtorvastatin Calcium Tablets
ContiansAtorvastin 10mg
Package100unit-dose/box
StoreStore atorvastatin calcium tablets at 20° - 25°C (68° - 77°F)
ApplicationAtorvastatin calcium tablet is an inhibitor of HMG-CoA reductase (statin) indicated as an adjunct therapy to diet to: 
Reduce the risk of MI, stroke, revascularization procedures, and angina in patients without CHD, but with multiple risk factors
Reduce the risk of MI and stroke in patients with type 2 diabetes without CHD, but with multiple risk factors
Reduce the risk of non-fatal MI, fatal and non-fatal stroke, revascularization procedures, hospitalization for CHF, and angina in patients with CHD
Reduce elevated total-C, LDL-C, apo B, and TG levels and increase HDL-C in adult patients with primary hyperlipidemia (heterozygous familial and nonfamilial) and mixed dyslipidemia
Reduce elevated TG in patients with hypertriglyceridemia and primary dysbetalipoproteinemia
Reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia (HoFH)
Reduce elevated total-C, LDL-C, and apo B levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia after failing an adequate trial of diet therapy
  
  

You Might Also Like